<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969666</url>
  </required_header>
  <id_info>
    <org_study_id>IPED2015CS02</org_study_id>
    <nct_id>NCT04969666</nct_id>
  </id_info>
  <brief_title>A Phase II, Repeat Single Oral Dose Study of IPED2015 in Healthy Male Subjects With Erectile Dysfunction</brief_title>
  <official_title>A Phase II, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Repeat Single Oral Dose Study of IPED2015 or Placebo in Otherwise Healthy Male Subjects With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Initiator Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Initiator Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomised, double-blind, parallel-group, placebo-controlled study to&#xD;
      investigate the effects of repeat single oral doses of IPED2015 in otherwise healthy male&#xD;
      subjects with ED.&#xD;
&#xD;
      Up to 120 subjects are planned to be enrolled into 3 groups. Group 1 is planned to consist of&#xD;
      60 subjects, Group 2 is planned to consist of 36 subjects and Group 3 is planned to consist&#xD;
      of 24 subjects. Groups 1, 2 and 3 will be conducted in parallel. Each subject will be dosed&#xD;
      on four occasions. There will be three study treatments of dose 1 of IPED2015, dose 2 of&#xD;
      IPED2015 or matched placebo. In each group, subjects will be randomised evenly to each of the&#xD;
      three study treatments and will receive the same treatment on each visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate the effects of repeat single oral doses&#xD;
      of IPED2015 on male subjects with erectile dysfunction (ED) on ability to develop and&#xD;
      maintain an erection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 4, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF-15) scale</measure>
    <time_frame>4 weeks</time_frame>
    <description>Erectile Dysfunction assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rigiscan (diagnosis and assessment of male sexual impotence)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Device to assess erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semen analysis (check of quality of semen)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Analysis of tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Assessment of patients health</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>IPED2015_dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPED2015_dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPED2015</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>IPED2015_dose 1</arm_group_label>
    <arm_group_label>IPED2015_dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Otherwise healthy male subjects with ED as determined from an IIEF-5 score of &lt;16, with a&#xD;
        body mass index of 18 to 35 kg/m2 (inclusive), of any ethnic origin.&#xD;
&#xD;
        Subject must have had at least one intent to have sexual intercourse during the last 3&#xD;
        months prior to Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any significant CNS, cardiac, pulmonary, metabolic, renal, hepatic (including Gilbert's&#xD;
        syndrome), gastrointestinal (GI) or psychiatric conditions, or history of fainting or&#xD;
        syncope or such condition that, in the opinion of the Investigator, may place the subject&#xD;
        at an unacceptable risk as a participant in the study, may interfere with the&#xD;
        interpretation of safety or tolerability data obtained in this study, or may interfere with&#xD;
        the absorption, distribution, metabolism or excretion of drugs, or with the completion of&#xD;
        treatment according to this Protocol.&#xD;
&#xD;
        Clinically significant history of abnormal physical or mental health interfering with the&#xD;
        study as determined by medical history and physical examinations obtained during Screening&#xD;
        or Day -7 as judged by the Investigator (including [but not limited to], neurological,&#xD;
        psychiatric, endocrine, cardiovascular, respiratory, GI, hepatic, or renal disorder).&#xD;
&#xD;
        Clinically significant abnormal laboratory results (including hepatic and renal panels,&#xD;
        complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or&#xD;
        physical findings at Screening. In case of uncertain or questionable results, tests&#xD;
        performed during the Screening visit may be repeated to confirm eligibility or judged to be&#xD;
        clinically irrelevant for otherwise healthy subjects with ED.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Westhead, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAC UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikael Thomsen</last_name>
    <phone>23276134</phone>
    <email>mt@initiatorpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claus Olesen</last_name>
    <phone>61260035</phone>
    <email>ceo@initiatorpharma.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

